Position in EXEL
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$227,660
-$94,271 QoQ
Shares Held
5,308
-27.7% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Savvy Advisors, Inc. holds $3,785,811 across 8 Biotechnology names. EXEL ranks #5 (6.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,181 | $1,685,127 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,821 | $813,149 | |
| 3 | INCY |
Incyte Corp
|
5,658 | $532,530 | |
| 4 | AGIO |
Agios Pharmaceuticals, Inc.
|
6,794 | $229,841 | |
| 5 | EXEL |
Exelixis, Inc.
This page
|
5,308 | $227,660 | |
| 6 | IBRX |
ImmunityBio, Inc.
|
24,175 | $185,422 | |
| 7 | CRVO |
CervoMed Inc.
|
25,922 | $102,132 | |
| 8 | ATNM |
Actinium Pharmaceuticals, Inc.
|
10,000 | $9,950 |
All Filings in EXEL
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $227,660 | 5,308 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $321,931 | 7,345 | Shares | Sole | 2026-01-20 | |
| No filing history on record for this holder in this stock. | ||||||